ProfileOfResearchers

Identified 54

TITLE: MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway
AUTHORS: Ramon Andrade De Mello; Pedro Nazareth Aguiar; Hakaru Tadokoro; Tallita Meciany Farias Vieira; Pedro Castelo Branco; Gilberto de Lima Lopes; Daniel Humberto Pozza ;
PUBLISHED: 2018, SOURCE: JOURNAL OF THORACIC DISEASE, VOLUME: 10, ISSUE: S16

INDEXED IN:

WOS

CrossRef: 8

IN MY:

ORCID

TITLE: What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
AUTHORS: Ramon Andrade De Mello; Luis Castelo-Branco; Pedro Castelo-Branco; Daniel Humberto Pozza ; Louis Vermeulen; Sofia Palacio; Matthew Salzberg; Craig C Lockhart;
PUBLISHED: 2018, SOURCE: American Society of Clinical Oncology Educational Book, ISSUE: 38

INDEXED IN:

CrossRef: 3

IN MY:

ORCID

TITLE: Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
AUTHORS: Ricardo Leão; Joana Dias Apolónio; Donghyun Lee; Arnaldo Figueiredo; Uri Tabori; Pedro Castelo-Branco;
PUBLISHED: 2018, SOURCE: Journal of Biomedical Science, VOLUME: 25, ISSUE: 1

INDEXED IN:

CrossRef: 161

IN MY:

ORCID

TITLE: MP37-08 SERUM MIRNA PREDICTS VIABLE DISEASE POST-CHEMOTHERAPY IN TESTICULAR NON-SEMINOMA GERM CELL TUMOR PATIENTS
AUTHORS: Ricardo Leão; Ton van Agthoven; Kamel Fadaak; Pedro Castelo-Branco; Michael Jewett; Joan Sweet; Ardalan E. Ahmad; Lynn Anson-Cartwright; Peter Chung; Aaron Hansen; Padraig Warde; Martin O’Malley; Philippe L. Bedard; Leendert H.J. Looijenga; Robert J Hamilton;
PUBLISHED: 2018, SOURCE: Journal of Urology, VOLUME: 199, ISSUE: 4S

INDEXED IN:

CrossRef

IN MY:

ORCID

TITLE: Epigenetic therapy in urologic cancers: An update on clinical trials
AUTHORS: Faleiro, I; Leão, R; Binnie, A; de Mello, RA; Maia, AT ; Castelo Branco, P;
PUBLISHED: 2017, SOURCE: Oncotarget, VOLUME: 8, ISSUE: 7

INDEXED IN:

Scopus

CrossRef: 35

IN MY:

ORCID

TITLE: The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer
AUTHORS: Faleiro, I; Apolonio, JD; Price, AJ; De Mello, RA; Roberto, VP; Tabori, U; Castelo Branco, P;
PUBLISHED: 2017, SOURCE: FUTURE ONCOLOGY, VOLUME: 13, ISSUE: 23

INDEXED IN:

Scopus

WOS

CrossRef: 19

IN MY:

ORCID

TITLE: Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy
AUTHORS: Ricardo Leão; Célia Domingos; Arnaldo Figueiredo; Robert Hamilton; Uri Tabori; Pedro Castelo-Branco;
PUBLISHED: 2017, SOURCE: Urologia Internationalis, VOLUME: 99, ISSUE: 2

INDEXED IN:

CrossRef: 56

IN MY:

ORCID

TITLE: A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker
AUTHORS: Aguiar, PN; Santoro, IL; Tadokoro, H; Lopes, GD; Filardi, BA; Oliveira, P ; Castelo Branco, P; Mountzios, G; de Mello, RA;
PUBLISHED: 2016, SOURCE: Immunotherapy, VOLUME: 8, ISSUE: 9

INDEXED IN:

Scopus

WOS

CrossRef

IN MY:

ORCID

TITLE: Telomere dysfunction and chromothripsis
AUTHORS: Aurélie Ernst; David T.W Jones; Kendra K Maass; Agata Rode; Katharina I Deeg; Billy Michael Chelliah Jebaraj; Andrey Korshunov; Volker Hovestadt; Michael A Tainsky; Kristian W Pajtler; Sebastian Bender; Sebastian Brabetz; Susanne Gröbner; Marcel Kool; Frauke Devens; Jennifer Edelmann; Cindy Zhang; Pedro Castelo‐Branco; Uri Tabori; David Malkin; Karsten Rippe; Stephan Stilgenbauer; Stefan M Pfister; Marc Zapatka; Peter Lichter; ...More
PUBLISHED: 2016, SOURCE: International Journal of Cancer, VOLUME: 138, ISSUE: 12

INDEXED IN:

CrossRef: 40

IN MY:

ORCID